Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6) | |
Wu, Yi-Long; Hirsh, Vera; Sequist, Lecia V.; Hu, Cheng-Ping; Feng, Jifeng; Lu, Shun; Huang, Yunchao; Schuler, Martin; Mok, Tony; Yamamoto, Nobuyuki | |
刊名 | PATIENT-PATIENT CENTERED OUTCOMES RESEARCH
![]() |
2018 | |
卷号 | 11期号:1 |
ISSN号 | 1178-1653 |
语种 | 英语 |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/3416440 |
专题 | 昆明医科大学 |
推荐引用方式 GB/T 7714 | Wu, Yi-Long,Hirsh, Vera,Sequist, Lecia V.,et al. Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)[J]. PATIENT-PATIENT CENTERED OUTCOMES RESEARCH,2018,11(1). |
APA | Wu, Yi-Long.,Hirsh, Vera.,Sequist, Lecia V..,Hu, Cheng-Ping.,Feng, Jifeng.,...&Yang, James Chih-Hsin.(2018).Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6).PATIENT-PATIENT CENTERED OUTCOMES RESEARCH,11(1). |
MLA | Wu, Yi-Long,et al."Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)".PATIENT-PATIENT CENTERED OUTCOMES RESEARCH 11.1(2018). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论